Clinical Trial Update: First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study [Phase 3]

View source ↗

Summary

Phase 3 study of first-line chemo with or without pembrolizumab in esophageal carcinoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Neoplasms | Phase 3 | Status: WITHDRAWN